Research Area D: Towards Integrative Therapy Concepts
Central question:
How can discoveries from the other areas be harnessed for innovative microbiome-based diagnostic, preventive, and therapeutic strategies?
Aim
Scientists in Research Area D will translate knowledge acquired in sections A, B and C into innovative, microbiome-centered, and personalized strategies of risk stratification, diagnosis, prevention and therapy against antibiotic-resistant bacterial pathogens (ARBPs). Notably, the resistomes of risk patients will be analyzed by metagenome sequencing of fecal samples and used to implement patient-specific therapies.

Moreover, combined resistome data will be used to adjust general antibiotic stewardship guidelines at the University Hospital Tübingen. In parallel, the commensals, the phages and the host-derived antimicrobial molecules with the capacity to selectively eliminate facultative pathogens from human microbiomes such as those identified in Research Area A, B, and C will be tested as promising agents to prevent infections by ARBPs.
Principal Investigators


University Hospital Tübingen
Diabetology, Endocrinology, Nephrology



Website

University of Tübingen
Institute for Tropical Medicine, Travel Medicine, Human Parasitology



Website

University of Tübingen
Institute for Tropical Medicine
Translationale Infectiology and Vaccine Development



Website

University Hospital Tübingen
Immunology and Oncology
Molecular Dermatology




Board Member, Coordinator Research Area D
University Hospital Tübingen
Internal Medicine II
Infectious Diseases and Translational Microbiome Sciences



Website

University of Tübingen
Institute for Ethics in Sciences and Humanities



Website